Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. Reply

N Engl J Med. 2022 Aug 25;387(8):762. doi: 10.1056/NEJMc2209529.

Authors

Luca Richeldi¹, Susanne Stowasser², Toby M Maher³

Affiliations

¹ Università Cattolica del Sacro Cuore, Rome, Italy [email protected].
² Boehringer Ingelheim International, Ingelheim am Rhein, Germany.
³ University of Southern California, Los Angeles, CA.

PMID: 36001725
DOI: 10.1056/NEJMc2209529

No abstract available

Publication types

Letter
Comment

MeSH terms

Cyclic Nucleotide Phosphodiesterases, Type 4
Humans
Idiopathic Pulmonary Fibrosis* / drug therapy
Phosphodiesterase 4 Inhibitors* / therapeutic use

Substances

Phosphodiesterase 4 Inhibitors
Cyclic Nucleotide Phosphodiesterases, Type 4